Betting On Biosimilars In China? Think Again
This article was originally published in PharmAsia News
Executive Summary
Interchangeability, reimbursement, approval delays: as the issues keep piling up, will biosimilars offer attractive opportunities for pharma firms in China? Executives from front-running biotechs and legal experts shared their views at a recent meeting in Shanghai.
You may also be interested in...
Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap
Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.
Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap
Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.
Chinese Firms At JPM Not About China, It’s Time To Go Global
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.